CAMBRIDGE, Mass., Nov. 3, 2022
/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"),
a clinical-stage biotechnology company pioneering the first
systematic approach to use mRNA therapeutics as a new class of
programmable epigenetic medicines, today announced that management
will participate in a fireside chat at the Jefferies London
Healthcare Conference on Tuesday, November
15, 2022, at 11:30 a.m. GMT
(6:30 a.m. ET).
A live webcast of the fireside chat will be available on the
Investors & Media section of the Company's website at
www.omegatherapeutics.com. An archived replay of the fireside chat
will be available on the same website for approximately 90
days.
About Omega Therapeutics
Omega Therapeutics, founded by Flagship Pioneering, is a
clinical-stage biotechnology company pioneering the first
systematic approach to use mRNA therapeutics as a new class of
programmable epigenetic medicines. The Company's OMEGA Epigenomic
Programming™ platform harnesses the power of epigenetics, the
mechanism that controls gene expression and every aspect of an
organism's life from cell genesis, growth, and differentiation to
cell death. Using a suite of technologies, paired with Omega's
process of systematic, rational, and integrative drug design, the
OMEGA platform enables control of fundamental epigenetic processes
to correct the root cause of disease by returning aberrant gene
expression to a normal range without altering native nucleic acid
sequences. Omega's modular and programmable mRNA medicines, Omega
Epigenomic Controllers™, target specific epigenomic loci within
insulated genomic domains, EpiZips, from amongst thousands of
unique, mapped, and validated genome-wide DNA-sequences, with high
specificity to durably tune single or multiple genes to treat and
cure diseases through Precision Genomic Control™. Omega is
currently advancing a broad pipeline of development candidates
spanning a range of disease areas, including oncology, regenerative
medicine, multigenic diseases including immunology, and select
monogenic diseases, including alopecia.
For more information, visit omegatherapeutics.com, or
follow us on Twitter and LinkedIn.
Contacts
Investor contact:
Eva Stroynowski
Omega Therapeutics
617.949.4370
estroynowski@omegatx.com
Media contact:
Jason
Braco
LifeSci Communications
646.751.4361
jbraco@lifescicomms.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/omega-therapeutics-to-participate-in-the-jefferies-london-healthcare-conference-301666519.html
SOURCE Omega Therapeutics
